You are here


The challenge of developing a clinical trial for an Ebola vaccine

October 09, 2017

The development of new vaccines and medicines is critical to responding to emerging health threats, such as Ebola. And, when lives are at stake, the response cannot be fast enough.

FHI 360’s Global Research Services conducts and supports high-quality clinical research in resource-limited settings around the world. In this audio interview, Ted FitzGerald, Director of Global Research Services, talks with Haddie Kiernan, Clinical Project Manager, about FHI 360’s quick work to set up an Ebola clinical trial in Sierra Leone, where virtually no clinical research had been conducted prior to the Ebola outbreak. Kiernan describes what it was like to start from scratch to set up office facilities and train staff — all while the epidemic was ongoing. The interview also provides an update on the immense progress that has been made since then to develop an Ebola vaccine.

FHI 360’s work to develop an Ebola vaccine was funded in whole or in part with federal funds from the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Contract No. HHSO1002014000021.

Learn more about FHI 360’s Global Research Services.

Homepage photo credit: Josh Vinson/FHI 360